Brawn Biotech Limited (BOM:530207)
India · Delayed Price · Currency is INR 21.05
-1.05 (-4.75%)
At close: Nov 6, 2026
Brawn Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 179.92 | 169.78 | 134.65 | 164.95 | 222.31 | 86.21 |
Other Revenue | 0.98 | - | 0 | - | 0.06 | 0 |
| 180.9 | 169.78 | 134.65 | 164.95 | 222.36 | 86.21 | |
Revenue Growth | 7.66% | 26.09% | -18.37% | -25.82% | 157.93% | -75.35% |
Cost of Revenue | 154.54 | 146.06 | 120.92 | 145.22 | 193.25 | 68.88 |
Gross Profit | 26.36 | 23.72 | 13.73 | 19.73 | 29.11 | 17.33 |
Selling, General & Admin | 8.87 | 7.1 | 11.44 | 17.04 | 15.94 | 21.91 |
Other Operating Expenses | 18.26 | 16.13 | 19.9 | 17.33 | 16.14 | 15.45 |
Operating Expenses | 28.32 | 24.45 | 32.49 | 35.36 | 33.17 | 37.9 |
Operating Income | -1.96 | -0.73 | -18.76 | -15.63 | -4.05 | -20.57 |
Interest Expense | -0.02 | -0.03 | -0.03 | -0.57 | -0.07 | -0.11 |
Interest & Investment Income | 0.84 | 0.84 | 0.82 | 0.88 | 0.03 | - |
Currency Exchange Gain (Loss) | -0.05 | -0.05 | -0.01 | -0.05 | - | 0.02 |
Other Non Operating Income (Expenses) | -0.02 | -0.02 | -0 | -0.01 | -0.02 | -0.52 |
EBT Excluding Unusual Items | -1.22 | 0.01 | -17.99 | -15.38 | -4.12 | -21.18 |
Gain (Loss) on Sale of Assets | - | - | 0.01 | -0.06 | - | - |
Pretax Income | -1.22 | 0.01 | -17.98 | -15.44 | -4.12 | -21.18 |
Income Tax Expense | -9.4 | -9.4 | -0.58 | -2.97 | 4.57 | -4.73 |
Net Income | 8.18 | 9.41 | -17.4 | -12.47 | -8.68 | -16.44 |
Net Income to Common | 8.18 | 9.41 | -17.4 | -12.47 | -8.68 | -16.44 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | 3 |
Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | 3 |
Shares Change | 11.28% | - | - | - | - | - |
EPS (Basic) | 2.64 | 3.14 | -5.80 | -4.16 | -2.89 | -5.48 |
EPS (Diluted) | 2.64 | 3.14 | -5.80 | -4.16 | -2.89 | -5.48 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 0.71 | 0.86 | -1.94 | -0.38 | 2.22 | -1.09 |
Free Cash Flow Per Share | 0.23 | 0.28 | -0.65 | -0.13 | 0.74 | -0.36 |
Gross Margin | 14.57% | 13.97% | 10.20% | 11.96% | 13.09% | 20.10% |
Operating Margin | -1.09% | -0.43% | -13.93% | -9.48% | -1.82% | -23.86% |
Profit Margin | 4.52% | 5.54% | -12.92% | -7.56% | -3.90% | -19.07% |
Free Cash Flow Margin | 0.39% | 0.50% | -1.44% | -0.23% | 1.00% | -1.27% |
EBITDA | -0.76 | 0.49 | -17.61 | -15.12 | -2.96 | -20.04 |
EBITDA Margin | -0.42% | 0.29% | -13.08% | -9.17% | -1.33% | -23.24% |
D&A For EBITDA | 1.2 | 1.22 | 1.15 | 0.51 | 1.09 | 0.53 |
EBIT | -1.96 | -0.73 | -18.76 | -15.63 | -4.05 | -20.57 |
EBIT Margin | -1.08% | -0.43% | -13.93% | -9.48% | -1.82% | -23.86% |
Revenue as Reported | 185.44 | 174.32 | 135.58 | 165.83 | 222.4 | 86.24 |
Advertising Expenses | - | 0.26 | 0.17 | 0.27 | 0.29 | 0.71 |